Srt Fabry Galafold denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for srt fabry galafold are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Galafold (Migalastat) on Medical-Necessity Grounds

Galafold is an oral chaperone therapy approved for adults with Fabry disease who have an amenable GLA mutation. Aetna's medical-necessity denials in this category almost always come down to one of three documentation gaps: the amenability status of the patient's specific mutation was not clearly established in the submitted record; the clinical severity of the patient's Fabry disease progression was not adequately documented; or the prescribing note did not explicitly address why Galafold is appropriate for this individual relative to enzyme replacement therapy alternatives.

Because Fabry disease is rare and the amenability determination is technically complex, reviewers who are not Fabry specialists frequently misread or overlook the genetic report. This makes the denial appealable in the majority of cases.

## Your Federal Appeal Rights

If you are in a non-grandfathered health plan, the ACA §2719 external review process gives you the right to have an independent review organization — staffed by clinicians unconnected to Aetna — examine the denial. You generally have around four months from the denial notice to request external review, though you should confirm the exact deadline on your Explanation of Benefits. If your condition is urgent, request an expedited external review, which compresses the timeline to days rather than weeks. ERISA §503 also requires that any employer-sponsored plan provide a full-and-fair review with meaningful access to the clinical criteria used.

## What to Gather Before You Appeal

• Diagnosis confirmation: Genetic sequencing report confirming the specific GLA mutation, along with a statement from a biochemical genetics laboratory or the assay used to determine whether the mutation is amenable per the FDA-approved prescribing label criteria.
• Clinical severity documentation: Chart notes, kidney function trends, cardiac imaging reports, pain assessments, and any organ involvement documentation that reflects the current stage of disease.
• Prior treatment history: If the patient has been on enzyme replacement therapy, include infusion records with dates, documented tolerability issues, or clinical response notes. If ERT-naive, document the clinical rationale.
• Prescriber medical-necessity letter: The treating physician (ideally a specialist in lysosomal storage disorders) should write a letter that maps every criterion in Aetna's published coverage policy to a specific fact in the chart.

## Criteria-Mapping Structure

Pull Aetna's current published medical policy for Galafold (available on Aetna's provider portal). List each coverage criterion verbatim in a table. Next to each criterion, write the specific chart fact that satisfies it — for example, the exact mutation name from the genetic report, the organ system involvement noted in clinic, and the amenability determination. This side-by-side mapping is the single most effective tool for overturning a medical-necessity denial because it removes any ambiguity about whether the patient qualifies. Attach the full prescribing label so the reviewer can verify the amenability framework used.